4Velders MP, Schreiber H, Kast WM. Active immunization against cancer cells : impediments and advances [J]. Semin Oncol, 1998,25 ( 6 ) :697 -706.
5Lygldakis NJ, Kosmidis P, Ziras N, et al. Combined transarterial targeting locoreglonal immunotherapy-chemotherapy for patients with unresectable hepatocenular carcinoma: a new alternative for an old problem[J] .J Interferon Cytokine Res, 1995,15(5):467-472.
6Kawata A, Une Y,Hosokawa M, et al. Adjuvant chemcoimmunotherapy for hepatocellular carcinorma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone [J]. Am J Clin Oncol, 1995,18(3) :257-262.
7Uchino J, Une Y, Kawata A, et al. Postoperative chemoimmunotherapy for the treatment of liver cancer [J]. Semin Surg Oncol, 1993,9 (4):332-335.
8Boehm U, Klamp T, Groot M, et al. Cellular response to interferongamma[J]. Ann Rev Immunol. 1997.15(1):749-795.
9Wadler S.The role of interferons in the treatment of solid tumors[J].Cancer, 1991,70[4 Suppl] :949-958.
10Mofikawa K. Recombinant interferon-alpha,-beta,and -gamma enhance the proliferative response of human B cells[J]. J Immunol, 1987, 139(3) :761.
